Global Blood Therapeutics (GBT) Reaches Agreement with FDA on Design of Phase 3 GBT440 Trial in SCD

Global Blood Therapeutics (GBT) Chief Medical Officer Ramos Retired

Global Blood Therapeutics (NASDAQ: GBT) disclosed the following n an SEC filing on Monday:

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On the conference call, the Company... More